Form 13-F position report

ENANTA PHARMACEUTICALS INC

Reported by JACOBS LEVY EQUITY MANAGEMENT INC

ENTA CUSIP 29251M106 Manager CIK 0000884414

Reported 278,423 shares, up 8,293 (3.1%) from the prior quarter.

Reported value -1.9%; share count 3.1% vs. the prior quarter.

Added
% of reported 13F value 0.13% This manager · Q1 2022
Shares 278,423 Quarter-end amount reported
Reported value $19,818,000 Fair value at quarter end
Consecutive quarters held 12 Through Q1 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 14419000
2021-12-31 20200000
2022-03-31 19818000
2022-06-30 14064000
2022-09-30 18274000
2022-12-31 16238179
2023-03-31 14010640
2023-06-30 7433247
2023-09-30 3860922
2023-12-31 5279208
2024-03-31 3399986
2024-06-30 2523534
2024-09-30 1986281
2024-12-31 1667563
2025-03-31 1472559
2025-06-30 1452049
2025-09-30 2023505
2025-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

18 quarters
Quarterly reported position history for ENANTA PHARMACEUTICALS INC held by JACOBS LEVY EQUITY MANAGEMENT INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2025 Reduced 0 -169,048 (-100.0%) 0 $0 2026-02-13
Q3 2025 Reduced 169,048 -23,022 (-12.0%) < 0.01% $2,023,505 2025-11-17
Q2 2025 Reduced 192,070 -74,698 (-28.0%) < 0.01% $1,452,049 2025-08-14
Q1 2025 Reduced 266,768 -23,243 (-8.0%) < 0.01% $1,472,559 2025-05-15
Q4 2024 Added 290,011 +98,285 (51.3%) < 0.01% $1,667,563 2025-02-14
Q3 2024 Reduced 191,726 -2,841 (-1.5%) < 0.01% $1,986,281 2024-11-14
Q2 2024 Reduced 194,567 -163 (-0.1%) 0.01% $2,523,534 2024-08-14
Q1 2024 Reduced 194,730 -366,291 (-65.3%) 0.02% $3,399,986 2024-05-15
Q4 2023 Added 561,021 +215,370 (62.3%) 0.03% $5,279,208 2024-02-14
Q3 2023 Reduced 345,651 -1,697 (-0.5%) 0.02% $3,860,922 2023-11-17
Q2 2023 Added 347,348 +893 (0.3%) 0.04% $7,433,247 2023-08-14
Q1 2023 Reduced 346,455 -2,603 (-0.7%) 0.09% $14,010,640 2023-05-15
Q4 2022 Reduced 349,058 -3,245 (-0.9%) 0.11% $16,238,179 2023-02-14
Q3 2022 Added 352,303 +54,771 (18.4%) 0.14% $18,274,000 2022-11-15
Q2 2022 Added 297,532 +19,109 (6.9%) 0.11% $14,064,000 2022-08-15
Q1 2022 Added 278,423 +8,293 (3.1%) 0.13% $19,818,000 2022-05-16
Q4 2021 Added 270,130 +16,316 (6.4%) 0.14% $20,200,000 2022-02-14
Q3 2021 Reduced 253,814 -5,739 (-2.2%) 0.1% $14,419,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

196 managers reported ENANTA PHARMACEUTICALS INC for Q1 2022.

Managers reporting ENANTA PHARMACEUTICALS INC in Q1 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 3,516,606 +45,191 < 0.01% $250,312,000 32 qtrs
VANGUARD GROUP INC Reduced 1,589,224 -36,685 < 0.01% $113,122,000 36 qtrs
FARALLON CAPITAL MANAGEMENT LLC Reduced 1,550,000 -23,829 0.53% $110,329,000 19 qtrs
STATE STREET CORPORATION Added 1,308,586 +181,517 < 0.01% $93,145,000 35 qtrs
ARMISTICE CAPITAL LLC Added 1,124,000 +68,000 1.55% $80,006,000 24 qtrs
RA CAPITAL MANAGEMENT L P New 964,212 +964,212 1.5% $68,633,000 1 qtr
NORTHERN TRUST CORPORATION Reduced 928,093 -84,071 0.01% $66,061,000 36 qtrs
FIRST MANHATTAN CO Reduced 789,311 -180,425 0.18% $56,183,000 23 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 607,100 -107,300 0.05% $43,213,000 25 qtrs
DIMENSIONAL FUND ADVISORS LP Reduced 593,520 -8,218 0.01% $42,244,000 29 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2022
Filed
May 16, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
242,496
Shared
0
None
35,927

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.